基于PTCy的单倍体相合与全相合同胞或无关供者减低强度预处理移植治疗DLBCL的比较
本回顾性研究比较了2008至2015年间接受首次非清髓/减低强度预处理异基因造血干细胞移植的复发弥漫大B细胞淋巴瘤成人患者,单倍体供者移植采用移植后环磷酰胺预防GVHD,并与全相合同胞供者及全相合无关供者移植比较。共纳入1438例患者,单倍体组3年总生存率46%、无进展生存率38%、非复发死亡率22%、复发/进展率41%,多因素分析显示与相合供者移植无显著差异。单倍体移植慢性GVHD累积发生率低于全相合同胞及全相合无关供者移植。
要点
- 单倍体移植3年OS 46%、PFS 38%、NRM 22%、复发/进展41%。
- 多因素分析显示单倍体移植与相合供者移植结局无显著差异。
- 单倍体移植慢性GVHD累积发生率低于全相合同胞及相合无关供者移植。
核心结论
- 基于PTCy的非清髓/减低强度预处理单倍体移植似乎是缺乏相合供者的DLBCL患者考虑异基因移植时有价值的替代选择。
研究设计与样本
- 回顾性比较非清髓/减低强度预处理异基因造血干细胞移植的长期结局。
- 纳入2008至2015年间接受首次非清髓/减低强度预处理异基因移植的成人DLBCL患者。
- 单倍体移植受者限于接受PTCy预防GVHD者,全相合同胞供者限于基于钙调神经磷酸酶抑制剂且未体内T细胞去除的方案,全相合无关供者接受基于钙调神经磷酸酶抑制剂的预防伴或不伴T细胞去除。
- 共纳入1438例患者:单倍体132例,全相合同胞供者525例,全相合无关供者T细胞去除阳性403例,T细胞去除阴性378例。
主要发现
- 单倍体供者组患者年龄显著更大、体能状态更好,且更常接受基于全身照射的预处理方案和骨髓移植物。
- 单倍体移植后3年总生存率46%、无进展生存率38%、非复发死亡率22%、复发/进展发生率41%。
- 多因素分析显示单倍体移植与相合供者移植的结局无显著差异。
- 单倍体移植慢性GVHD累积发生率低于全相合同胞供者及全相合无关供者T细胞去除阳性/阴性组。
关键数值与推荐
- 单倍体移植3年总生存率46%、无进展生存率38%、非复发死亡率22%、复发/进展发生率41%。
临床怎么用
- 作者认为,基于PTCy的非清髓/减低强度预处理单倍体移植似乎是缺乏相合供者的DLBCL患者考虑异基因移植时有价值的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study retrospectively compared long-term outcomes of nonmyeloablative/reduced intensity conditioning (NMC/RIC) allogeneic hematopoietic cell transplantation (allo-HCT) from a haploidentical family donor (haplo-HCT) using posttransplant cyclophosphamide (PTCy) with those of matched sibling donor (MSD) and matched unrelated donor (MUD) with or without T-cell depletion (TCD+/TCD-) in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Adult patients with DLBCL who had undergone their first NMC/RIC allo-HCT between 2008 and 2015 were included. Recipients of haplo-HCT were limited to those receiving graft-versus-host disease (GVHD) prophylaxis with PTCy. GVHD prophylaxis in MSD was limited to calcineurin inhibitor (CNI)-based approaches without in vivo TCD, while MUD recipients received CNI-based prophylaxis with or without TCD. Outcome analyses for overall survival (OS) and progression-free survival (PFS), nonrelapse mortality (NRM), and disease relapse/progression were calculated. A total of 1438 patients (haplo, 132; MSD, 525; MUD TCD+, 403; and MUD TCD-, 378) were included. Patients with haplo donors were significantly older, had a better performance status and had more frequently received total body irradiation-based conditioning regimens and bone marrow grafts than MSD and MUD TCD+ or TCD-. 3-year OS, PFS, NRM and relapse/progression incidence after haplo-HCT was 46%, 38%, 22%, and 41%, respectively, and not significantly different from outcomes of matched donor transplants on multivariate analyses. Haplo-HCT was associated with a lower cumulative incidence of chronic GVHD compared with MSD, MUD TCD+/TCD-. NMC/RIC haplo-HCT with PTCy seems to be a valuable alternative for patients with DLBCL considered for allo-HCT but lacking a matched donor.
引用
- Dreger P, Sureda A, Ahn KW, et al. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Adv. 2019. PMID: 30723110. doi:10.1182/bloodadvances.2018027748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。